STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in Refractory Chronic RhinosinusitisArticle Published on 2023-12-132024-09-05 Journal: medRxiv [Category] update2024, [키워드] CD4 Chronic Refractory Sinusitis cohort study CRS flow cytometry Phosphorylation STAT4 T-cells [DOI] 10.1101/2023.12.11.23299743 PMC 바로가기 [Article Type] Article
Recent clinical findings on the role of kinase inhibitors in COVID-19 managementCOVID-19 관리에서 키나제 억제제의 역할에 대한 최근 임상 결과Review Published on 2022-10-012022-09-11 Journal: Life sciences [Category] 변종, 신약개발, 임상, 치료제, [키워드] activator affected alleviate Anti-inflammatory anti-viral effects antiviral agent Antiviral agents BTK clinical evidence Clinical finding Clinical practice clinical trial Complication complications Consequences coronavirus disease COVID-19 COVID-19 patient COVID-19 patients CRS cytokine release storm drug Efficacy glycogen synthase GSK-3 highly pathogenic inhibitor inhibitors JAK/STAT janus Janus kinase kinase Kinase inhibitor kinase inhibitors kinases management MAPK Novel coronavirus novel coronavirus disease outbreak p38 MAPK pandemic paradigm shift performed pharmacological pharmacological intervention protein kinase recent Signaling STAT therapy Transcription trials Viral load [DOI] 10.1016/j.lfs.2022.120809 PMC 바로가기 [Article Type] Review
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancerArticle Published on 2022-10-012022-11-15 Journal: Thoracic cancer [Category] 진단, [키워드] accompanied adverse events Cancer Cancer immunotherapy Cancer patients Cardiopulmonary caused Cell Colitis COVID-19 infection CRS cytokine release Cytokine release syndrome develop diagnosed diagnosed with COVID-19 diarrhea disease dose drugs examination Factors Fever Immune checkpoint inhibitor immune-related adverse events. Infection intensive care interleukin-6 Ipilimumab lung adenocarcinoma lung cancer nivolumab Patient patients postoperative returned SARS-CoV-2 syndrome systemic inflammatory the patient Treatment variety was performed with COVID-19 [DOI] 10.1111/1759-7714.14632 PMC 바로가기
Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational studyArticle Published on 2022-09-012022-11-15 Journal: São Paulo medical journal = Revista paulista de medicina [Category] 진단, 치료기술, [키워드] Admission age Analysis analyzed C-reactive protein (CRP Chest Clinical characteristics Comparative conducted Coronavirus disease 2019 COVID-19 COVID-19 patient CRP CRP level CRS Cytokine release syndrome database died disease evaluate ferritin high mortality hospital Hospitalized IL-6 independent risk factor information interleukin-6 laboratory parameter Logistic regression analysis lymphocyte Mortality neutrophil no difference oxygen saturation Patient performed receiving Research retrospective severe COVID-19 patient Signal transduction significantly lower suppresse survival group survived the patient Tocilizumab tocilizumab administration treated Treatment Turkey WBC White blood cell [DOI] 10.1590/1516-3180.2021.0604.R1.23112021 PMC 바로가기
Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19)코로나바이러스 감염증(COVID-19) 환자의 치료 효능 및 임상 안전성에 대한 토실리주맙(인간화 단클론항체) 평가Article Published on 2022-08-102022-09-12 Journal: Medicina [Category] SARS, 진단, [키워드] activated acute respiratory distress added adverse effect airways alanine aminotransferase alkaline phosphatase ALP ALT Analysis Anticoagulant ARDS assessment Autoimmune Bacterial baseline C-reactive protein characterized clinical coagulation parameter Coagulopathy control group COVID-19 COVID-19 cases COVID-19 patient COVID-19 patients CRP CRS Cytokine release syndrome Cytokine storm D-dimer discharged Efficacy Endpoint expired fatality ferritin Follow-up humanized monoclonal antibody include infection rate Inflammatory inflammatory conditions inflammatory parameter inflammatory parameters INR institution institutional protocol International lactate dehydrogenase LDH Manifestations material normalized patients of COVID-19 Platelet Pneumonia presenting Prothrombin time provided Pulmonary edema raised receiving respiratory tract infection Result Safety severe COVID-19 patients severe disease significantly higher statistically significant difference survival rate syndrome Teaching the disease the patient therapeutic efficacy Tocilizumab treat Treatment Treatment protocol treatment regimen was performed [DOI] 10.3390/medicina58081076 PMC 바로가기 [Article Type] Article
Interleukin 6: A biomarker for COVID-19 progressionResearch article Published on 2022-08-022022-10-05 Journal: Sensors (Basel, Switzerland) [Category] 바이오마커, 신약개발, 임상, 치료제, [키워드] “cytokine storm” Biomarker caused China clinical trial Concentration COVID COVID-19 COVID-19 progression CRS cytokine Cytokine release syndrome Cytokine storm Diagnosis disease Health highlight IL-6 IL-6 level immune system immunoregulation Infection Inflammation inhibited interleukin interleukin-6 massive inflammatory monoclonal antibodies monoclonal antibody morbidity and mortality multi-organ dysfunction pandemic Patient pleiotropic pro-inflammatory cytokines progression receptor reduce reducing Respiratory failure resulting SARS-CoV-2 serum severe complications severity of COVID-19 significantly therapeutic target through contact transmitted Treatment World Health Organization zoonotic [DOI] 10.1016/j.matpr.2022.07.387 [Article Type] Research article
Differential susceptibility to SARS-CoV-2 in the normal nasal mucosa and in chronic sinusitis정상 비점막 및 만성 부비동염에서 SARS-CoV-2에 대한 감수성 감수성Article Published on 2022-08-012022-09-11 Journal: European Journal of Immunology [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] ACE2 ACE2-expressing cell ACE2-expressing cells acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral immune response association Brain chronic Chronic rhinosinusitis close monitoring coronavirus CRS Culture deficiency disease eosinophils Eosinophils Human nasal mucosa Evidence gene expression difference gene expression differences high risk Human increase in individuals Infection investigated lung mechanism nasal nasal mucosa other organ other organs Patient progression reservoir respiratory tract rhinosinusitis SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 viral infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Subtypes suggested susceptibility susceptible tissue tissue culture Transmission viral infection viral replication [DOI] 10.1002/eji.202249805 PMC 바로가기 [Article Type] Article
Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases면역 요법 및 인간 질병에서 사이토카인 방출에 기여하는 게놈 결정인자의 식별Article Published on 2022-07-282022-09-11 Journal: Journal of Translational Medicine [Category] Coronavirus, 유전자 메커니즘, [키워드] abrogate Analysis Autoimmune diseases CAR CAR T-cell therapy CD22 cells cellular Cohort cohorts collected contribute contributing to CRS cytokine release Cytokine release syndrome dataset determinant develop driving drugs targeting expression Frequency genomic Glycolysis human disease identification immune system Immunotherapy IMPROVE in vivo Infection Influenza influenza infection influenza infections lupus erythematosus management mRNA not increased occur outcomes pathway Patient patients with influenza PFKFB4 PFKFB4. platform Prevent reaction reduce RNA extraction severity SLE syndrome systemic lupus erythematosus T-cell T-cells targeted therapy therapy tissues Treatment Tumor upregulated was used were used while with COVID-19 [DOI] 10.1186/s12967-022-03531-3 PMC 바로가기 [Article Type] Article
Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia급성 전골수구성 백혈병 환자의 항 SARS-CoV2 항체 매개 사이토카인 방출 증후군Case Reports Published on 2022-06-132022-09-12 Journal: BMC Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Activation Acute promyelocytic leukemia acute respiratory distress ADE Administered administration Admission advanced age adverse event Anemia antibody antibody treatment Antibody-dependent enhancement APL approach Bone marrow bruise Case report Clinical deterioration complex Coronavirus disease 2019 COVID-19 symptoms CRS Cytokine release syndrome death Diagnosis disease evidenced exacerbated Factor female hematological high risk highlight IL-10 IL-6 IL-8 immune immune activation immunization Infection Inpatients Laboratory leukemia leukemic life-threatening limit nasal passive immunization Patient positive potential risk radiological rapid increase reported SARS-CoV-2 SARS-CoV-2 RT-PCR SARS-CoV-2 testing SARS-CoV2 serum cytokine severe COVID-19 syndrome tested theoretical risk therapeutic therapy-related immunosuppression throat swab TNFα viral burden viral infection [DOI] 10.1186/s12879-022-07513-0 PMC 바로가기 [Article Type] Case Reports
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy Research Published on 2022-06-012022-10-05 Journal: Nature cancer [Category] 임상, 진단, 치료기술, 치료법, [키워드] 95% CI absence Adverse adverse event analyzed Cancer Cancer immunotherapy Cancer therapy clinically Cohort cohort study common condition COVID-19 vaccination COVID-19 vaccines CRS CXCL8 cytokine level Cytokine release syndrome Cytokines Diagnosis eight elevated event Hospitalized immune immune response immune-checkpoint inhibitor interleukin-6 modulate observé occurred Patient patients died receive response Serious Adverse Event serum serum cytokine single-center Symptoms therapy Treatment Tumor upregulated vaccination [DOI] 10.1038/s43018-022-00398-7 [Article Type] Research